HLB stocks hit the daily limit up at 39,700 won (+29.95%) at 9:07 AM on Sept 28, following FDA approval of its cholangiocarcinoma drug Rieflecto (lirafugratinib). The US subsidiary Eleva Therapeutics received approval on Sept 23 (local time) for Rieflecto as a second-line treatment for adult patients with unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or rearrangement. This marks the first instance of a Korean pharmaceutical company directly submitting and obtaining FDA approval for a global oncology drug through a New Drug Application (NDA). The approval was based on the global Phase 1/2 'ReFocus' clinical trial, which demonstrated a 45.7% objective response rate (ORR) in the approved patient population. HLB plans to launch Rieflecto in the US market in Q4, representing a regulatory milestone for Korean pharmaceutical companies entering the global oncology market.
FDA Approves Rieflecto for FGFR2-Altered Cholangiocarcinoma Treatment
Eleva Therapeutics, HLB's US subsidiary, received FDA approval on Sept 23 (local time) for Rieflecto (lirafugratinib) as a second-line treatment for adult patients with unresectable locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusion or rearrangement. HLB stated this represents the first case of a Korean pharmaceutical or biotechnology company directly submitting an NDA to the FDA and obtaining approval for a global oncology drug. The stock opened at the daily limit up in both the NextTrade (NXT) pre-market session and the regular trading session on Sept 28, reflecting strong buying interest following the FDA approval announcement during the Chuseok holiday period.
ReFocus Trial Demonstrates 45.7% Response Rate in Target Population
The global Phase 1/2 'ReFocus' clinical trial served as the basis for FDA approval. In the approved patient population, the trial demonstrated an objective response rate (ORR) of 45.7%, a median duration of response (mDOR) of 11.8 months, and a median progression-free survival (mPFS) of 11.3 months. These clinical endpoints supported the regulatory decision to authorize Rieflecto for the specified patient group with FGFR2 fusion or rearrangement cholangiocarcinoma.
HLB Plans Q4 US Launch and European Market Entry
HLB plans to launch Rieflecto in the US market in Q4 following the FDA approval. The company is simultaneously pursuing European market entry, with Eleva submitting a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) on Sept 14 for the cholangiocarcinoma treatment. HLB is also conducting the 'ReFocus202' tumor-agnostic clinical trial targeting solid tumors with FGFR2 fusion or rearrangement, expanding the drug's pipeline beyond cholangiocarcinoma indications.
FAQ
What did the FDA approve for HLB on Sept 23?
The FDA approved Rieflecto (lirafugratinib) on Sept 23 (local time) as a second-line treatment for adult patients with unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or rearrangement. This approval was based on the global Phase 1/2 'ReFocus' clinical trial, which demonstrated a 45.7% objective response rate in the approved patient population.
Why did HLB stocks hit the daily limit up on Sept 28?
HLB stocks hit the daily limit up at 39,700 won (+29.95%) on Sept 28 following the FDA approval of Rieflecto. The approval represents the first instance of a Korean pharmaceutical company directly obtaining FDA approval for a global oncology drug through an NDA submission, driving strong buying interest in both pre-market and regular trading sessions.
When will HLB launch Rieflecto in the US market?
HLB plans to launch Rieflecto in the US market in Q4 following the FDA approval received on Sept 23. The company also submitted a Marketing Authorization Application to the European Medicines Agency on Sept 14 for European market entry.